Status | Study |
RECRUITING |
Study Name: Efficacy of Methimazole Dosing Algorithm Condition: Graves Disease Date: 2023-07-17 Interventions: Testing dosing algorithm for efficacy. |
RECRUITING |
Study Name: Study to Evaluate the Safety and Efficacy of Batoclimab in Participants With Graves' Disease (GD) Condition: Date: 2023-05-15 Interventions: Batoclimab is a fully human anti-neonatal fragment crystallizable receptor (FcRn) monoclonal antibody. |
RECRUITING |
Study Name: Study to Evaluate the Safety and Efficacy of Batoclimab in Participants With Graves' Disease (GD) Condition: Date: 2023-05-15 Interventions: Batoclimab is a fully human anti-neonatal fragment crystallizable receptor (FcRn) monoclonal antibody. |
RECRUITING |
Study Name: Preoperative Corticosteroids in Autoimmune Thyroid Disease Condition: Graves Disease Date: 2022-01-25 Interventions: Will take Dexamethasone pre-operatively |
Not yet recruiting |
Study Name: HIFU vs RAI in the Relapsed Graves' Disease Condition: Graves Disease Date: 2017-01-04 Interventions: Device: Echopulse Replacing HIFU for the Graves' disease patients who traditionally have RAI to remissio |
Completed |
Study Name: Effects Of Oral Alfacalcidol On Maturation Of Dendritic Cells In Graves' Disease Patients Condition: Graves Disease Date: 2016-12-07 Interventions: Drug: 1α-D3 patients were |
Recruiting |
Study Name: ATX-GD-59 in Patients With Graves Disease Not Treated With Anti-thyroid Therapy Condition: Graves Disease Date: 2016-11-14 Interventions: Biological: ATX-GD-59 Disease specific immune modulating treatment for Graves Disease |
Recruiting |
Study Name: K1-70 - A Study in Subjects With Graves' Disease Condition: Graves' Disease Date: 2016-08-18 Interventions: Drug: K1-70 intramuscular Each subject will receive one dose of K1-70 by IM injection on the morning of |
Completed |
Study Name: Prevalence of Circulating Parvovirus Genome in Recently Diagnosed Graves' Disease: a Case-control Study Condition: Graves Disease Date: 2016-06-09 Interventions: Biological: serodiagnosis |
Recruiting |
Study Name: A Study to Evaluate the Safety and Effect of CFZ533 on Patients With Graves' Disease Condition: Graves' Disease Date: 2016-03-15 Interventions: Drug: CFZ533 Patients will receive CFZ533 intravenously over approximately one hour |